Progress in drug therapy for multidrug-resistant Acinetobacter baumannii infection

doi:10.12092/j.issn.1009-2501.2019.10.015

Abstract

Abstract:

Acinetobacter baumannii is a common pathogen that causes infections in the respiratory tract, blood flow, urinary tract and abdominal cavity. In recent years, the drug resistance rate of Acinetobacter baumannii to commonly used clinical drugs has increased year by year. It has been reported that multidrug-resistant, extensively drug-resistance and even pandrug-resistance strains are widely spread all over the world, which brings great challenges to clinical treatment. Therefore, the purpose of this paper is to review the drug treatment and the latest progress of multi-drug-resistant Acinetobacter baumannii.

Key words: Acinetobacter baumannii, multi-drug resistance, therapeutic drugs, review

CLC Number:

R969.3

FU Peishu, SUN Fengjun, FENG Wei, XIONG Lirong, LI Xiaoyu, XIA Peiyuan. Progress in drug therapy for multidrug-resistant Acinetobacter baumannii infection[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(10): 1181-1187.

References

［1］Peleg AY,Seifert H,Paterson DL.Acinetobacter baumannii: emergence of a successful pathogen［J］.Clin Microbiol Rev，2008，21(3):538-582.
［2］Durante-Mangoni E,Zarrilli R.Global spread of drug-resistant Acinetobacter baumannii: molecular epidemiology and management of antimicrobial resistance［J］.Future Microbiol，2011，6(4):407-422.
［3］Lemos EV,de la Hoz FP, Einarson TR,et al.Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis［J］.Clin Microbiol Infect，2014，20(5):416-423.
［4］Landman D,Georgescu C,Martin DA,et al.Polymyxins revisited［J］.Clin Microbiol Rev，2008，21(3):449-465.
［5］Ziaka M,Markantonis SL,Fousteri M,et al.Combined intravenous and intraventricular administration of colistin methanesulfonate in critically ill patients with central nervous system infection［J］.Antimicrob Agents Chemother，2013，57(4):1938-1940.
［6］Zavascki AP, Goldani LZ, Li J,et al.Polimixin B for the treatment of multidrug-resistant pathogens: a critical review［J］.J Antimicrob Chemother，2007，60(6):1206-1215.
［7］Assamali Z,Jain R,Danziger LH.An update on the arsenal for multidrug-resistant Acinetobacter infections :polymyxin antibiotics［J］.Int J Infect Dis,2015，30 :125-132.
［8］Quintanilha JCF,Duarte NDC,Lloret GR,et al.Colistin and polymyxin B for treatment of nosocomial infections in intensive care unit patients: pharmacoeconomic analysis［J］.Int J Clin Pharm，2019，41(1):74-80.
［9］Aggarwal R,Dewan A.Comparison of nephrotoxicity of Colistin with Polymyxin B administered in currently recommended doses: a prospective study［J］.Ak Ann Clin Microbiol Antimicrob，2018，17(1):15.
［10］Yoon J,Urban C,Terzina C, et al.In vitro double and triple synergistic activities of polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii［J］. Antimicrob Agents Chemother，2004，48(3)：753-757.
［11］Tripodi M-F,Durante-Mangoni E,Fortunato R,et al.Comparative activities of colistin, rifampicin, imipenem, sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases［J］.Int J Antimicrob Agents，2007，30(6)：537-540.
［12］Zusman O,Avni T,Leibovici L,et al.Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems［J］.Antimicrob Agents Chemother，2013，57(10)：5104-5111.
［13］O'Hara JA,Ambe LA,Casella LG,et al.Activities of vancomycin-containing regimens against colistin-resistant Acinetobacter baumannii clinical strains［J］.Antimicrob Agents Chemother，2013，57(5)：2103-2108.
［14］Paul M,Daikos GL,Durante-Mangoni E,et al.Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial［J］.Lancet Infect Dis，2018，18(4):391-400.
［15］Chung ES,Ko KS.Eradication of persister cells of Acinetobacter baumannii through combination of colistin and amikacin antibiotics［J］.J Antimicrob Chemother，2019,74(5):1277-1283.
［16］Altun S,Kocak TZ,Altun B,et al.Growing OXA-23 type strains among carbapenem-resistant Acinetobacter baumannii and tigecycline as an alternate combination therapy［J］.Turk J Med Sci，2016，6(6):1894-1899．
［17］Sun JR,Chan MC,Chang TY,et al.Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS［J］.Antimicrob Agents Chemother，2010，4(11):4934-4938．
［18］Freire AT,Melnyk V,Kim MJ,et al.Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia［J］.Diagn Microbiol Infect Dis，2010，68(2):140-151.
［19］Liang CA,Lin YC,Lu PL,et al.Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii［J］.Clin Microbiol Infect，2018，24(8):908.e1-908.e7.
［20］Ni W,Han Y,Zhao J,et al.Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis［J］.Int J Antimicrob Agents，2016，47(2):107-116.
［21］Ramirez J,Dartois N,Gandjini H,et al.Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia［J］.Antimicrob Agents Chemother，2013，57(4):1756-1762.
［22］Fernández-Cuenca F,Martínez-Martínez L,Conejo MC,et al.Relationship between β-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii［J］.J Antimicrob Chemother，2003，51(3):565-574.
［23］Krizova L,Poirel L,Nordmann P,et al.TEM-1β-lactamase as a source of resistance to sulbactam in clinical strains of Acinetobacter baumannii［J］. J Antimicrob Chemother，2013，68(12):2786-2791.
［24］Housman ST,Hagihara M,Nicolau DP,et al.In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam,doripenem and tigecycline alone and incombination against multidrug-resistant Acinetobacter baumannii［J］.J Antimicrob Chemother，2013，68(10):2296-2304.
［25］Jaruratanasirikul S,Wongpoowarak W,Aeinlang N,et al.Pharmacodynamics modeling to optimize dosage regimens of sulbactam［J］.Antimicrob Agents Chemother，2013，57(7):3441-3444.
［26］Betrosian AP,Frantzeskaki F,Xanthaki A,et al.Efficacy and safety of high-dose ampicillin/sulbactam vs.colistinas monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia［J］.J Infect，2008，56(6):432-436.
［27］Khawcharoenporn T,Pruetpongpun N,Tiamsak P,et al.Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia ［J］.Int J Antimicrob Agents，2014，43(4):378-382.
［28］Pachon-Ibanez ME,Docobo-Perez F,Lopez-Rojas L,et al.Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii［J］.Antimicrob Agents Chemother，2010，54(3)：1165-1172.
［29］Nordqvist H,Nilsson LE,Claesson C.Mutant prevention concentration of colistin alone and in combination with rifampicin for multidrug-resistant Acinetobacter baumannii［J］.Eur J Clin Microbiol Infect Dis，2016，35(11):1845-1850.
［30］AL-Shaer M,Nazer LH,Kherallah M.Rifampicin as adjunct to colistin therapy in the treatment of multidrug-resistant Acinetobacter baumannii［J］.Ann Pharmacother，2014，48(6):766-771.
［31］Mohammadi M,Khayat H,Sayehmiri K,et al.Synergistic effect of colistin and rifampin against multidrug resistant Acinetobacter baumannii:A systematic review and meta-analysis［J］.Open Microbiol J，2017，11:63-71.
［32］Giannouli M,Di Popolo A,Durante-Mangoni E,et al.Molecular epidemiology and mechanisms of rifampicin resistance in Acinetobacter baumannii isolates from Italy［J］.Int J Antimicrob Agents，2012，39(1):58-63.
［33］Pachon-Ibanez ME, Docobo-Perez F,Lopez-Rojas L,et al.Efficacy of rifampin and its combinations with imipenem,sulbactam,and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii［J］.Antimicrob Agents Chemother，2010，54(3)：1165-1172.
［34］Durante-Mangoni E,Signoriello G,Andini R,et al.Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter,randomized clinical trial［J］.Clin Infect Dis，2013，57(3):349-358.
［35］Santimaleeworagun W,Wongpoowarak P,Chayakul P,et al.In vitro activity of colistin or sulbactam in combination with fosfomycin orimipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases［J］.Southeast Asian J Trop Med Public Health，2011，42(4)：890-900.
［36］Sirijatuphat R,Thamlikitkul V.Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections［J］.Antimicrob Agents Chemother，2014，58(9):5598-5601．
［37］Menegucci TC,Albiero J,Migliorini LB,et al.Strategies for the treatment of polymyxin B-resistant Acinetobacter baumannii infections［J］.Int J Antimicrob Agents，2016，47(5)：380-385.
［38］Shinohara DR, Menegucci TC, Fedrigo NH,et al.Synergistic activity of polymyxin B combined with vancomycin against carbapenem-resistant and polymyxin-resistant Acinetobacter baumannii: first in vitro study［J］.J Med Microbiol，2019，68(3):309-315.
［39］Wareham DW, Gordon NC, Hornsey M.In vitro activity of teicoplanin combined with colistin versus multidrug-resistant strains of Acinetobacter baumannii［J］.J Antimicrob Chemother，2011，66(5), 1047-1051.
［40］Hornsey M,Longshaw C,Phee L,et al.In vitro activity of telavancin in combination with colistin versus Gramnegative bacterial pathogens［J］.Antimicrob Agents Chemother，2012，56(6)：3080-3085.
［41］Phee L,Hornsey M,Wareham DW.In vitro activity of daptomycin in combination with low-dose colistin against a diverse collection of Gram-negative bacterial pathogens［J］.Eur J Clin Microbiol Infect Dis,2013,32(10):1291-1294.
［42］Hornsey M,Phee L,Longshaw C,In vivo efficacy of telavancin/colistin combination therapy in a Galleria mellonella model of Acinetobacter baumannii infection［J］.Int J Antimicrob Agents,2013,41(3):285-287.
［43］Ceccarelli G,Oliva A, d'Ettorre G,et al.The role of vancomycin in addition with colistin and meropenem against colistin-sensitive multidrug resistant Acinetobacter baumannii causing severe infections in a Paediatric Intensive Care Unit［J］.BMC Infect Dis, 2015,30:15:393.
［44］acho-Montero J, Amaya-Villar R,Gutiérrez-Pizarraya A, et al.Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii ［J］.Chemotherapy,2013,59(3):225-231.
［45］Jacobs MR,Abdelhamed AM,Good CE,et al.Activity of Cefiderocol(S-649266), a Siderophore cephalosporin, against gram-negative bacteria, including carbapenem-resistant nonfermenters and entero bacteriaceae with defined extended-spectrum β-lactamases and carbapenemases［J］.Antimicrob Agents Chemother,2018,21,63(1):pii: e01801-18.
［46］Hackel MA, Tsuji M, Yamano Y, et al.In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of Gramnegative bacilli collected worldwide in 2014-2016［J］.Antimicrob Agents Chemother,2018,62(2):pii:e01968-1017.
［47］Hackel MA,Tsuji M,Yamano Y,et al.In vitro activity of the siderophore cephalosporin,cefiderocol,against a recent collection of clinically relevant Gram-negative bacilli from North America and Europe, including carbapenem non-susceptible isolates: the SIDERO-WT-2014 study［J］. Antimicrob Agents Chemother,2017,61(9):pii:e00093-17.
［48］Dobias J,Dénervaud-Tendon V,Poirel L,et al.Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens［J］.Eur J Clin Microbiol Infect Dis,2017,36(12):2319-2327.
［49］Ito A,Sato T,Ota M,et al. In vitro antibacterial properties of cefiderocol, a novel siderophore cephalo-sporin, against Gram-negative bacteria［J］.Antimicrob Agents Chemother,2017,62(1).pii:e01454-517.
［50］Contreras DA, Fitzwater SP, Nanayakkara DD, et al. Co-infections of two strains of NDM-1 and OXA-232 co-producing Klebsiella pneumoniae in a kidney transplant patient［J］. Antimicrob Agents Chemother, 2019, Sep 16. pii: AAC.00948-19. doi: 10.1128/AAC.00948-19.
［51］Dobias J, Dénervaud-Tendon V, Poirel L,et al.Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens［J］.Eur J Clin Microbiol Infect Dis,2017,36(12):2319-2327.
［52］Ito A,Kohira N,Bouchillon SK, et al. In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria［J］.J Antimicrob Chemother,2016,71(3):670-677.
［53］Kazmierczak KM,Tsuji M,Wise MG,et al.In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study)［J］. Int J Antimicrob Agents,2019,53(2):177-184.
［54］Portsmouth S,Van Veenhuyzen D,Echols R,et al.Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial［J］.Lancet Infect Dis,2018,18(12):1319-1328.
［55］Zhanel GG,Cheung D,Adam H, et al.Review of eravacycline,a novel fluorocycline antibacterial agent［J］.Drugs,2016,76(5):567-588.
［56］Seifert H,Stefanik D,Sutcliffe JA,et al.In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii［J］.Int J Antimicrob Agents,2018,51(1):62-64.
［57］Zhanel GG,Baxter MR,Adam HJ,et al.In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014-2015［J］.Diagn Microbiol Infect Dis,2018,91(1):55-62.
［58］Livermore DM, Mushtaq S,Warner M,et al.In vitro activity of eravacycline against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii［J］.Antimicrob Agents Chemother,201,60(6):3840-3844.
［59］Abdallah M,Olafisoye O,Cortes C,et al.Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City［J］.Antimicrob Agents Chemother,2015,59(3):1802-1805.
［60］Solomkin JS,Ramesh MK,Cesnauskas G,et al. Phase 2,randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections［J］.Antimicrob Agents Chemother,2014,58(4):1847-1854.
［61］Rodvold KA,Gotfried MH,Isaacs RD,et al.Plasma and Intrapulmonary concentrations of ETX2514 and sulbactam following intravenous administration of ETX2514SUL to healthy adult subjects［J］.Antimicrob Agents Chemother,2018,62(11).pii: e01089-18.
［62］Durand-Réville TF,Guler S,Comita-Prevoir J,et al.ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacterbaumannii［J］.Nat Microbiol,2017,2:17104.

[1]	WANG Lin, YU Jianguo, LI Xiao, LUAN Jiajie. Establish and implement a pre-prescription system for outpatient based on Six Sigma DMAIC model [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 780-787.
[2]	HU Kangyi, CAO Linzhong, WAN Chaochao, SHANG Zhengya, YANG Xiaorui, ZHANG Yongjie. Research progress of traditional Chinese medicine regulating mitochondrial function in the treatment of steroid-induced femoral head necrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 688-696.
[3]	SHE Zhihua, CHEN Zhou, LIANG Songyue. Construction of informatization system of drug clinical trials ethical review based on cloud architecture [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1023-1030.
[4]	Pazilaiti YASEN, YUAN Hao, LU Hong, ZHENG Ya, WANG Yuping, ZHOU Yongning. Research progress in clinical trials of targeted drugs for gastric cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 454-461.
[5]	WANG Nana, TAN Xiaofeng, MA Tao, CHENG Yusheng. Current situation and future perspectives of treatment of chronic pulmonary aspergillosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 217-222.
[6]	TIAN Jing, MENG Qiuhua, LIANG Qiuyun, DONG Min. Research progress in the associations of metabolic diseases and therapeutic drugs with hepatocellular carcinomas [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 103-110.
[7]	WEI Liuping, WU Qing, YIN Nange, YANG Bin, MAO Jinxiao. Effect and safety of lactoferrin for prevention of late-onset sepsis in premature neonates: a systematic review [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 653-660.
[8]	WU Jiaqi, YANG Qiaowen, CHEN Xiumin, HUANG Runyue, HUANG Qingchun, ZHAO Yue, WU Xiaodong. Efficacy and safety of iguratimod combined with methotrexate in rheumatoid arthritis: A systematic review and Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(10): 1132-1140.
[9]	ZHANG Chunyan, FAN Xiaodong, QIN Yuan, KONG Wenqiang, ZHOU Chunyang, DU Biao. Markov model to assess long-term effects of teneligliptin in treatment of type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(1): 65-72.
[10]	LI Nan，HUANG Haitao，YONG Xiaolan. Pharmaceutical care for a patient misdiagnosed as Staphylococcus intermedius pulmonary infection [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(9): 1067-1071.
[11]	LUO Xue-mei, YAN Si-min, GE Wei-hong. Epidural anesthesia compared with combined spinal epidural anesthesia for femoral head replacement in the elderly: a systematic review [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(8): 890-897.
[12]	SUN Wen-xiong, GE Xiao-zhen, LI Jian, YUAN Zhao, LUO Xu-jun, JIN Gao-feng. Exploration of how to strengthen the ethical review of medical apparatus clinical trials [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(3): 323-325.
[13]	RUAN Guan-yu, XU Qiu-xing, CAI Hui-ya, DENG Jie, SHI Dao-hua. Comparison of neonatal outcomes in women with gestational diabetes mellitus treated with metformin or insulin: a systematic review [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(10): 1139-1143.
[14]	WANG Hong, HU Long-hua, NING Chang-xiu, HANG Ya-ping, ZHONG Qiao-shi, HU Xiao-yan, ZHANG Bai-ling, JIA Kun-ru. Study on the mechanism of carbapenem resistance in Acinetobacter baumannii [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(10): 1093-1098.
[15]	HE Xian-di, YAN Pei-e, ZHOU Qi, WANG Hua-xue. Effects of Xuebijing for injection on neutrophil TCTP expression in Acinetobacter baumannii sepsis rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(1): 29-32.